These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 35464465)
1. Chaperones and Catalysts: How Antigen Presentation Pathways Cope With Biological Necessity. Margulies DH; Taylor DK; Jiang J; Boyd LF; Ahmad J; Mage MG; Natarajan K Front Immunol; 2022; 13():859782. PubMed ID: 35464465 [TBL] [Abstract][Full Text] [Related]
2. Structural and dynamic studies of TAPBPR and Tapasin reveal the mechanism of peptide loading of MHC-I molecules. Margulies DH; Jiang J; Natarajan K Curr Opin Immunol; 2020 Jun; 64():71-79. PubMed ID: 32402827 [TBL] [Abstract][Full Text] [Related]
3. Chaperone function in antigen presentation by MHC class I molecules-tapasin in the PLC and TAPBPR beyond. Margulies DH; Jiang J; Ahmad J; Boyd LF; Natarajan K Front Immunol; 2023; 14():1179846. PubMed ID: 37398669 [TBL] [Abstract][Full Text] [Related]
10. Structure and Function of Molecular Chaperones that Govern Immune Peptide Loading. Margulies DH; Jiang J; Natarajan K Subcell Biochem; 2019; 93():321-337. PubMed ID: 31939156 [TBL] [Abstract][Full Text] [Related]
11. A loop structure allows TAPBPR to exert its dual function as MHC I chaperone and peptide editor. Sagert L; Hennig F; Thomas C; Tampé R Elife; 2020 Mar; 9():. PubMed ID: 32167472 [TBL] [Abstract][Full Text] [Related]
12. Interaction of TAPBPR, a tapasin homolog, with MHC-I molecules promotes peptide editing. Morozov GI; Zhao H; Mage MG; Boyd LF; Jiang J; Dolan MA; Venna R; Norcross MA; McMurtrey CP; Hildebrand W; Schuck P; Natarajan K; Margulies DH Proc Natl Acad Sci U S A; 2016 Feb; 113(8):E1006-15. PubMed ID: 26869717 [TBL] [Abstract][Full Text] [Related]
13. Dynamics of peptide loading into major histocompatibility complex class I molecules chaperoned by TAPBPR. Xu H; Song K; Da LT Phys Chem Chem Phys; 2022 May; 24(20):12397-12409. PubMed ID: 35575131 [TBL] [Abstract][Full Text] [Related]
14. TAPBPR employs a ligand-independent docking mechanism to chaperone MR1 molecules. McShan AC; Devlin CA; Papadaki GF; Sun Y; Green AI; Morozov GI; Burslem GM; Procko E; Sgourakis NG Nat Chem Biol; 2022 Aug; 18(8):859-868. PubMed ID: 35725941 [TBL] [Abstract][Full Text] [Related]
15. Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules. Ilca FT; Neerincx A; Wills MR; de la Roche M; Boyle LH Proc Natl Acad Sci U S A; 2018 Oct; 115(40):E9353-E9361. PubMed ID: 30213851 [TBL] [Abstract][Full Text] [Related]
16. Get into the groove! The influence of TAPBPR on cargo selection. Satti R; Morley JL; Boyle LH Curr Opin Immunol; 2023 Aug; 83():102346. PubMed ID: 37295041 [TBL] [Abstract][Full Text] [Related]
17. Crystal structure of a TAPBPR-MHC I complex reveals the mechanism of peptide editing in antigen presentation. Jiang J; Natarajan K; Boyd LF; Morozov GI; Mage MG; Margulies DH Science; 2017 Nov; 358(6366):1064-1068. PubMed ID: 29025991 [TBL] [Abstract][Full Text] [Related]
18. MHC I chaperone complexes shaping immunity. Thomas C; Tampé R Curr Opin Immunol; 2019 Jun; 58():9-15. PubMed ID: 30771631 [TBL] [Abstract][Full Text] [Related]
19. TAPBPR: a new player in the MHC class I presentation pathway. Hermann C; Trowsdale J; Boyle LH Tissue Antigens; 2015 Mar; 85(3):155-66. PubMed ID: 25720504 [TBL] [Abstract][Full Text] [Related]
20. Preferential interaction of MHC class I with TAPBPR in the absence of glycosylation. Neerincx A; Boyle LH Mol Immunol; 2019 Sep; 113():58-66. PubMed ID: 30077416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]